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Abstract
Background: Dementia and cognitive impairment could severely impact patients’ life and bring heavy burden to
patients, caregivers and societies. Some interventions are suggested for the older patients with these conditions to
help them live well, but economic evaluation is needed to assess the cost-effectiveness of these interventions. Trial-
based economic evaluation is an ideal method; however, little is known about the tools used to collect data of resource
use and quality of life alongside the trials. Therefore, the aim of this review is to identify and describe the resource use
and quality of life instruments in clinical trials of interventions for older patients with dementia or cognitive impairment.
Methods: We will perform a search in main electronic databases (Ovid MEDLINE, PsycINFO, EMBASE, CINAHL, Cochrane
Databases of Systematic Reviews, Web of Science and Scopus) using the key terms or their synonyms: older, dementia,
cognitive impairment, cost, quality of life, intervention and tools. After removing duplicates, two independent reviewers
will screen each entry for eligibility, initially by title and abstract, then by full-text. A hand search of the references of
included articles and general search, e.g. Google Scholar, will also be conducted to identify potential relevant studies. All
disagreements will be resolved by discussion or consultation with a third reviewer if necessary. Data analysis will be
completed and reported in a narrative review.
Discussion: This review will identify the instruments used in clinical trials to collect resource use and quality of life data
for dementia or cognitive impairment interventions. This will help to guide the study design of future trial-based
economic evaluation of these interventions.
Systematic review registration: PROSPERO CRD42016038495
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Introduction
As the population ages rapidly, the prevalence of demen-
tia and cognitive impairment is a growing public health
concern worldwide and it has been estimated to increase
within the next 20 years [1]. These two disorders could
impact patients’ cognitive function, behaviour and activ-
ities of daily living, and have become one of the principal
causes of disability and decreased quality of life (QoL)
among older people [2]. It is increasingly recognised that
psychosocial interventions contribute to the care of
people with dementia and their families in a wide range
of domains [3]. For example, the sensory rehabilitation
has been shown to improve patients’ QoL and increase
their social engagement, which could help them live well
with dementing conditions [4].
In light of expanding health care costs and finite
budget, cost-effectiveness analysis is essential for na-
tional health care decisions and resource allocation. The
outcome of effectiveness used in such analysis is the
quality-adjust life years (QALYs), which take both the
quantity and quality of life into account. In dementia re-
search, QoL has been recognised as an important
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measure as the clinical efficacy measure [5]. Several in-
struments have specifically been developed to assess
QoL in dementia [2, 6, 7]. According to the most recent
systematic review [6], more than 10 QoL measures were
identified and properties assessed, but this review was
limited to disease-specific QoL measures only, and
such measures may not be used directly to generate
health utility scores for QALYs calculations in cost-
effectiveness analysis.
Among the methods available to assess health care in-
terventions, trial-based economic evaluations are consid-
ered as an ideal vehicle for data generation because of
the availability of patient-level data and unbiased esti-
mates of clinical outcomes [8]. But more information is
needed on the tools for data collection alongside the
trials. Schölzel-Dorenbos et al. [2] performed a system-
atic review in 2006 on the use of QoL measures as an
outcome in intervention trials in patients with mild cog-
nitive impairment or dementia and found only three
studies and two QoL scales. Following this review, a lot
of new QoL instruments were developed and widely
used, e.g., Dementia Quality of Life questionnaire
(DEMQOL) [9] and dementia specific quality of life in-
strument (QUALIDEM) [10].
Resource use is also an essential component in the
cost-effectiveness analysis. Instruments are recom-
mended for cost data collection to improve the quality
and uniformity of data generated from trials, suggested
by the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) [11]. The Resource Utilisa-
tion in Dementia (RUD) instrument is a standardised
tool and the most widely used instrument for resource
use data collection in dementia [12]. It has been used
in several clinical drug trials for Alzheimer’s disease
[13–15] and several observational studies [16–18]. But
there is a lack of information about the use of RUD
in clinical trials for dementia or cognitive impairment,
especially for non-pharmacological interventions, and
whether there are other instruments available to collect
resource use data in such trials is yet unknown.
Therefore, in this review, we aim to identify and de-
scribe the resource use and QoL instruments that have
been used in clinical trials of dementia or cognitive im-
pairment interventions.
Methods
This review will follow the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) State-
ment [19] and consists of acquiring, extracting and
assessing the data. This protocol is in accordance with
the PRISMA-Protocols (PRISMA-P) 2015 checklist [20]
(Additional file 1: Table S1 for the PRISMA-P 2015
checklist)
Eligibility criteria
Studies fulfilling the following criteria will be included in
the systematic review:
 Population—older adults with dementia or cognitive
impairment
 Intervention—all types of interventions, both drug
and nondrug therapies
 Comparator—no intervention or the usual care
 Outcomes—measurement and reporting of QoL, or
resource use or both
 Study type—randomised clinical trial, or feasibility
study or pilot study
No language restrictions will be imposed during the
literature search but the abstract should be available in
English. There is no restriction on date of publication.
All studies should be original research published in a
peer-reviewed journal. For the definition of ‘older adults’
used in this review, we will accept any age cut-off if a
study describes their population as being ‘older adults’.
The definition of ‘patients with dementia or cognitive
impairment’ will also be based on each individual study.
The outcomes should be measured using standardised
questionnaires or tools. Quality of life is an abstract and
broad concept including physical function, perceptions
of well-being, satisfaction, and sense of self-worth. Given
the aim to guide cost-effectiveness analysis study design,
quality of life, quality-adjusted life years, health utility
and QALY will be used as the search terms.
Information sources
The following major databases for the discipline of
medicine and nursing will be searched: Ovid MEDLINE,
PsycINFO, EMBASE, CINAHL, Cochrane Databases of
Systematic Reviews, Web of Science and Scopus. The
systematic search will be conducted in September 2016,
and the searches will be re-run just before the final ana-
lyses to retrieve further studies for inclusion. A hand
search of the references of included articles and general
search, e.g. Google Scholar, will also be conducted to
identify potential relevant studies.
Search strategy
Key terms have been determined through discussion be-
tween two authors (FY and BG). The following terms or
their synonyms will be used: older, dementia, cognitive
impairment, cost, quality of life, intervention and tools.
The search terms used in Ovid MEDLINE can be found
in Additional file 2: Table S2. The search strategies will
be created specifically for each database using relevant
index and free text terms. The titles and abstracts of all
identified studies potentially eligible for inclusion in the
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review will be screened. Full-text versions of the in-
cluded articles will be obtained.
Data management
All results from database and hand searches will be
exported into Endnote X7 software (Thomson Reuters,
2016). Duplicates will be removed using a standard func-
tion before each entry will be screened from eligibility.
After dropping duplicates, all the titles and abstracts of
the studies retrieved will be imported to an Excel
spreadsheet (Microsoft Corporation, 2010) for screening.
Study selection
Study selection will be undertaken in two stages: first,
titles and abstracts will be screened against the inclusion
criteria; second, the full-text for all eligible articles will
be screened to confirm whether or not the study should
be included in the final review. Two authors (FY and
BG) will carry out the selection process. If there are dis-
crepancies and the two investigators cannot reach a con-
sensus, the disagreements will be resolved through
discussion and consultation with a third reviewer (PD).
Data extraction
One review author (FY) will extract data using a stan-
dardised data extraction form developed for this review
(Additional file 3: Table S3). A second author (BG) will
then verify the extracted data. Any discrepancies will be
resolved through discussion or adjudication by a third
author (PD), until consensus is reached. The data
extracted for this review will include:
1. Publication characteristics (title, year of publication,
author, study objective, type of study);
2. Participant characteristics (country, inclusion
criteria, exclusion criteria, age, sex, and disease, e.g.
mild cognitive impairment, dementia, or both);
3. Intervention characteristics (what intervention, type
of intervention, duration of intervention and
comparator);
4. Outcome characteristics (whether a cost/QoL measure
was used, what instrument or instruments used, time
points at which the instrument was assessed, patient/
proxy reported, and type of QoL measure).
If any of the previously described data is not clearly
presented in the research article, we will contact the
authors for clarification by sending emails.
Quality assessment
Since the aim of this review is to identify and describe mea-
sures of resource use and QoL in trials, without reporting
quantitative evaluation of measurement properties or trial
effect estimates, the quality of included studies will
not be assessed.
Data synthesis
First, the characteristics of included studies will be tabulated
based on the data extracted using Additional file 3:
Table S3. Second, the frequency of each resource use or
QoL instrument used in the trials will be reported. Third,
the characteristic of each measurement instrument will be
summarised using a table (Additional file 4: Table S4),
which is based on the summary table used in one system-
atic review of dementia-specific QoL scales [6], and will
include instrument name, conceptual basis, patient report
(Yes/No), proxy report (Yes/No), patient population, sub-
scales, items, response options and scoring. One author
(FY) will summarise the results, and a second researcher
(BG) will review and highlight any discrepancies.
Disagreements between the two authors will be resolved
by discussion, with involvement of a third review author
(PD) where necessary.
Discussion
The main aim of this review is to identify and describe
the tools/instruments used in clinical trials to collect
data of resource use and QoL for dementia or cognitive
impairment interventions. The results of the review will
provide information about potentially useful instruments
in future similar trials and contribute to the study design
of trial-based economic evaluation of dementia or cogni-
tive impairment interventions. We anticipate that the re-
view will be useful to a variety of stakeholders who have
an interest in dementia and cognitive impairment care.
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